32.32 USD
↗ 0.39 (1.22%)AT CLOSE (11:59 AM EDT)
Zenas BioPharma, Inc. Common Stock
ZBIONASDAQ • USD
32.00
↘ 0.32 (0.99%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
32.00
↘ 0.32 (0.99%)
Market: CLOSED
Zenas BioPharma, Inc. Common Stock (ZBIO) trades at $32.33 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, ZBIO is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Sep 16, 2026.
Open?$31.89
High?$33.23
Low?$31.59
Prev. Close?$31.93
Volume?746.4K
Avg. Volume?660.5K
VWAP?$32.47
Rel. Volume?1.13x
Bid / Ask
Bid?$26.80 × 100
Ask?$38.42 × 100
Spread?$11.62
Midpoint?$32.61
Valuation & Ratios
Market Cap?2.1B
Shares Out?65.2M
Float?31.2M
Float %?47.8%
P/E Ratio?N/A
P/B Ratio?8.42
EPS?-$7.43
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Employees
167
Market Cap
2.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2024-09-13
Address
852 WINTER STREET, SUITE 250
WALTHAM, MA 02451
Phone: 857-271-2954
WALTHAM, MA 02451
Phone: 857-271-2954
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?1
Momentum?50
Short Sent.?10
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.39Distress
Confidence?57%Low
Short InterestSqueeze Risk
Short % of Float?37.55%Squeeze Risk
Short Interest?11.7M
Days to Cover?14.2
Free Float31.2M
Avg Daily Volume825.0K
Settlement Date2026-08-31
Financial Health
Current Ratio?9.93Strong
Quick Ratio?9.93Strong
Cash Ratio?2.99Strong
Debt/Equity?1.20Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?8.42HIGH▾
Peers100
S&P22
P/S?2,081.09HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-4.6CHEAP▾
S&P97
EV/Sales?2,181.53HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-196.0%WEAK▾
S&P3
ROA?-69.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-225974000
Enterprise Value?$2.2B
Fundamentals ratios updated end of day